Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBT Margin: 2022-2025

Historic EBT Margin for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Sep 2025 value amounting to 7.55%.

  • Arcutis Biotherapeutics' EBT Margin rose 10036.00% to 7.55% in Q3 2025 from the same period last year, while for Sep 2025 it was -13.62%, marking a year-over-year increase of 12710.00%. This contributed to the annual value of -70.92% for FY2024, which is 36364.00% up from last year.
  • Per Arcutis Biotherapeutics' latest filing, its EBT Margin stood at 7.55% for Q3 2025, which was up 139.58% from -19.07% recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' EBT Margin registered a high of 3,507.40% during Q1 2022, and its lowest value of -14,856.41% during Q3 2022.
  • In the last 3 years, Arcutis Biotherapeutics' EBT Margin had a median value of -92.81% in 2024 and averaged -479.46%.
  • Over the last 5 years, Arcutis Biotherapeutics' EBT Margin had its largest YoY gain of 1,471,727bps in 2023, and its largest YoY loss of 638,766bps in 2023.
  • Arcutis Biotherapeutics' EBT Margin (Quarterly) stood at -2,432.25% in 2022, then surged by 194,239bps to -489.86% in 2023, then spiked by 47,520bps to -14.67% in 2024, then skyrocketed by 10,036bps to 7.55% in 2025.
  • Its last three reported values are 7.55% in Q3 2025, -19.07% for Q2 2025, and -37.63% during Q1 2025.